Crystallization of microparticulate pure polymorphs of active pharmaceutical ingredients using CO 2-expanded solvents
Visualitza/Obre
Cita com:
hdl:2117/16497
Tipus de documentArticle
Data publicació2012-04-04
Condicions d'accésAccés obert
Llevat que s'hi indiqui el contrari, els
continguts d'aquesta obra estan subjectes a la llicència de Creative Commons
:
Reconeixement-NoComercial-SenseObraDerivada 3.0 Espanya
Abstract
The feasibility of the Depressurization of an Expanded Liquid Organic Solution
(DELOS) method to process different active pharmaceutical ingredients (APIs) as finely divided
powders with narrow particle size distribution, high crystallinity degree, high polymorphic purity,
and free from residual solvent has been demonstrated. Cholesterol, acetylsalicylic acid (aspirin),
naproxen, acetaminophen, and ibuprofen were chosen as model drugs. It has been demonstrated
that the supersaturation ratio attained during crystallization from CO2-expanded solvents can be
modulated through appropriate variations of process parameters CO2 content and
concentration of the initial solution. In view of the potential application that compressed fluidsbased
technologies have in the pharmaceutical industry, a preliminary scalability study of the
process in compliance with the constraints imposed by the Good Manufacturing Practices (GMP)
specifications is presented herein
CitacióSala, S. [et al.]. Crystallization of microparticulate pure polymorphs of active pharmaceutical ingredients using CO 2-expanded solvents. "Crystal growth and design", 04 Abril 2012, vol. 12, núm. 4, p. 1717-1726.
ISSN1528-7483
Col·leccions
Fitxers | Descripció | Mida | Format | Visualitza |
---|---|---|---|---|
criystallization.pdf | 431,4Kb | Visualitza/Obre |